Introduction
Antineutrophil cytoplasmic autoantibodies (ANCAs) are associated with a distinctive group of necrotizing small vessel vasculitides that typically have a paucity of vascular deposition of immunoglobulin and complement [1 ] . This distinguishes ANCA disease from disease caused by antiglomerular basement membrane antibodies (anti-GBM disease) and classic immune complex disease, both of which have conspicuous deposition of immunoglobulin in vessel walls. However, even though pauci-immune ANCA disease does not have much immunoglobulin in vessel walls, there is substantial evidence supporting a pathogenic role for ANCA. Pauci-immune necrotizing and crescentic glomerulonephritis is a frequent component of ANCA disease. The pathologic and immunohistologic features of glomerulonephritis are indistinguishable in the different clinicopathologic variants of ANCA disease, including Wegener's granulomatosis (granulomatosis with polyangiitis), microscopic polyangiitis, Churg-Strauss syndrome (allergic granulomatosis with polyangiitis), and renal-limited pauciimmune necrotizing and crescentic glomerulonephritis. Two major target antigens for ANCAs are myeloperoxidase (MPO) and proteinase 3 (PR3), which are proteins in the primary granules of neutrophils and the lysosomes of monocytes. More recently, autoantibodies against human lysosomal-associated membrane protein 2 (LAMP-2) have been reported in patients with either MPO-ANCA or PR3-ANCA [2, 3] . This review will summarize evidence that supports a pathogenic role for ANCAs.
On the basis solely of pathologic findings, in 1954 Godman and Churg [4] proposed that Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome might have a common pathogenesis. The close association of circulating ANCAs with these diseases supports the relatedness of these clinicopathologic syndromes and suggests a common pathogenesis. Additional clinical observations that support but do not prove a pathogenic role for ANCAs are the correlation of ANCA titers with response to treatment, the value of anti-B cell therapy and plasma exchange in treatment [5, 6 ], the induction of pauci-immune small vessel vasculitis in patients who develop ANCAs secondary to drug treatment [7, 8] , and the correlation of ANCA disease with higher levels of ANCA target antigens on the surface of circulating neutrophils [9, 10] . There is also one intriguing report of a neonate who developed pulmonary and renal disease after transplacental passage of MPO-ANCA IgG from a mother with microscopic polyangiitis [11] . This raises the possibility that the infant developed ANCA disease; however, no pathologic confirmation was obtained and no additional corroborating cases have been reported.
In-vitro observations supporting pathogenicity of antineutrophil cytoplasmic autoantibodies
Many in-vitro studies demonstrate mechanisms by which ANCAs could cause vasculitis in vivo (Fig. 1) . For example, incubation of ANCA IgG with neutrophils that have been primed with cytokines causes the release of destructive granule enzymes and toxic reactive oxygen radicals [12] . This increases the expression of ANCA antigens on the surface of neutrophils where they can interact with ANCAs to cause neutrophil activation [13] . ANCA activation of neutrophils is mediated by both engagement of Fc receptors by immunoglobulin bound to MPO or PR3 [14, 15] as well as by the binding of ANCA Fab 0 2 to ANCA antigens on the surface of neutrophils [16, 17] . ANCAs bind not only to ANCA antigens at the surface of neutrophils and monocytes, but also to ANCA antigens adsorbed onto endothelial cells and other tissue constituents at sites of injury [17] . Leukocytes activated by ANCAs in vitro release mediators that are injurious to endothelial cells [18] [19] [20] . In-vitro activation of neutrophils by ANCAs also stimulates the release of neutrophil extracellular traps (NETs) that contain chromatin and granule proteins including MPO ] also observed the linkage of PR3 with CD177 and found evidence that this complex interacts with the complement receptor Mac-1 to induce neutrophil activation. The interaction of PR3 with associated molecules may play an important role not only in the activation of neutrophils by PR3-ANCA, but also in the presentation of PR3 as an antigen to the immune system [25 ] .
As mentioned earlier, ANCA disease is associated with higher levels of ANCA target antigens on the surface of circulating neutrophils [9, 10] . In addition, patients with ANCA disease have aberrant transcription of PR3 and MPO genes in circulating neutrophils, which normally is shut off before neutrophils are released from the bone marrow [26] . Ciavatta et al.
[27 ] have discovered that this aberrant overexpression of genes for ANCA target antigens (MPO and PR3) in ANCA disease patients is the result of disturbed epigenetic regulation. An understanding of the expression and display of ANCA autoantigens may help understand both the genesis of the autoimmune response and the pathogenic interaction with ANCA, which could point to novel therapies. 
Animal models of antineutrophil cytoplasmic autoantibody disease
Several animal models of ANCA disease have been described [28 ] . Intravenous injection of anti-MPO IgG into mice causes a pauci-immune necrotizing glomerulonephritis and a pauci-immune systemic small vessel vasculitis that is pathologically identical to human ANCA disease [29] . Another mouse model has been produced by transplanting wild-type (Mpoþ/þ) bone marrow cells into irradiated MPO knockout (MpoÀ/À) mice or vice versa [30] . Bone marrow-derived cells are sufficient and necessary for anti-MPO to cause glomerulonephritis and vasculitis in this model because chimeric MpoÀ/À mice with circulating MPOþ/þ neutrophils develop glomerulonephritis, whereas chimeric Mpoþ/þ mice with circulating MPOÀ/À neutrophils do not [29] . Disease in mouse models is enhanced by systemic administration of proinflammatory factors [31] , ameliorated by anti-tumor necrosis factor (TNFa) [31] , and prevented by the depletion of neutrophils [32] or by inactivation of the alternative pathway of complement activation [33] [34] [35] . In vitro, ANCA-activated neutrophils release factors that activate complement [33, 35] . Activation of complement generates C5a, which is a potent neutrophil chemoattractant and activator. Recent studies implicate the engagement of C5a receptors as an important event in the induction of disease in these mouse models [34, 35] .
These observations raise the possibility that therapy aimed at blocking complement activation might be feasible in human ANCA disease. Two recent studies using mouse models of MPO-ANCA disease suggest even more novel treatment strategies. Schreiber et al. [36 ] found that phosphoinositol 3 kinase-gamma isoform (PI3Kg), which is required for a number of signaling pathways Antineutrophil cytoplasmic autoantibody vasculitis Jennette et al. 265
Figure 1 Immunogenesis and pathogenesis of antineutrophil cytoplasmic autoantibody disease
Diagram of putative events in the pathogenesis of antineutrophil cytoplasmic autoantibody (ANCA) disease based on in-vitro and in-vivo experimental observations. In the upper left, the theory of autoimmunity induced by an immune response to a complementary peptide is depicted. The lower left proposes that T cell regulation is disturbed to allow persistence and progression of autoimmunity. In the upper right, the aberrant increased production of ANCA antigens by epigenetic dysregulation of gene expression is illustrated. Once ANCA antibodies are present along with neutrophils with increased antigens, the sequence of pathogenic events illustrated in the lower right can occur, that is cytokines or other priming factors induce neutrophils to express more ANCA antigens at the cell surface where they are available for binding to ANCAs, which activates neutrophils by both Fc receptor engagement and Fab 0 2 binding. Factors released by neutrophils activate the alternative complement pathway, which generates factors that amplify recruitment and activation of neutrophils. Activated neutrophils release toxic factors that cause inflammatory injury to endothelial cells and vessel walls. Reproduced with permission of J.C. Jennette. involved in neutrophil activation, plays a pivotal role in disease induced by anti-MPO in mice. PI3Kg-deficient mice were protected against disease induction, and a PI3Kg inhibitor prevented disease induction in vivo and blocked activation of neutrophils by ANCAs in vitro. Van Timmeren et al. [37 ] used a different strategy to attenuate disease induction by anti-MPO IgG. They used a bacterial endoglycosidase to treat the pathogenic anti-MPO IgG, which abrogates Fc receptor engagement and complement activation by the IgG but does not interfere with antigen binding. The hydrolyzed anti-MPO IgG was ineffective in vitro in activating neutrophils and did not cause disease when injected into mice. These studies suggest that treatments that modify either ANCAs or effector neutrophils might be effective in ANCA disease.
A rat model of ANCA disease can be induced by immunizing rats with human MPO, which induces anti-MPO antibodies that crossreact with human and rat MPO [38] .
As in the mouse model [31] , anti-rat TNF antibodies ameliorate disease in this rat model [39] . Of interest with respect to these observations are recent clinical studies that suggest a role for anti-TNF therapy in ANCA disease patients [40 ,41 ] .
Although there are several credible animal models of MPO-ANCA disease, there has been less success with producing a compelling model of PR3-ANCA disease, which has led some to question the pathogenicity of anti-PR3 antibodies and to invoke other pathogenic mechanisms for PR3-ANCA disease, such as T cell-mediated inflammation. Until recently, the most promising model was described by Pfister et al. [42] , who produced antibodies against recombinant murine PR3 mice deficient in PR3 and elastase. Mice injected with these anti-PR3 antibodies developed enhanced subcutaneous inflammation at sites injected with TNFa, but did not develop glomerulonephritis or vasculitis. In 2010, Primo et al. [43 ] reported a more convincing model. They immunized autoimmunity prone nonobese diabetic (NOD) mice with recombinant mouse PR3 in complete Freund's adjuvant, resulting in high levels of circulating anti-PR3. No disease developed; however, when splenocytes from these immunized mice were transferred into immune deficient NOD-severe combined immunodeficiency (SCID) mice, the mice developed necrotizing glomerulonephritis and vasculitis. Control mice that received splenocytes from nonimmunized mice developed no disease, supporting a specific effect caused by PR3 immunization. This is a promising model but additional studies are required to confirm and elucidate the mechanism underlying the glomerulonephritis and vasculitis. In an ex-vivo rat model, Hattar et al. [44 ] used isolated rat lungs to investigate the pathogenicity of anti-PR3 antibodies. Rat lungs were perfused with human neutrophils primed with TNF and monoclonal anti-PR3 antibodies.
This induced marked weight gain in the lungs due to increased capillary permeability and edema but no overt vasculitis in the lungs. Again, this is an interesting model but more studies are required to understand the underlying mechanisms and their relevance to human ANCA disease.
As mentioned earlier, antibodies to LAMP-2 have been reported to occur in high frequency in patients with active PR3-ANCA and MPO-ANCA disease [2,3]. Kain et al.
[3] also reported evidence that anti-LAMP-2 antibodies are pathogenic in rats. Anti-LAMP-2 antibodies caused pauci-immune necrotizing glomerulonephritis when injected into rats. As discussed below, crossreactive antibodies induced by immunization with a bacterial protein that has homology to LAMP-2 also caused disease in rats. These observations are extremely important because they raise the possibility that antibodies to LAMP-2 are as important if not more important than antibodies to MPO or PR3 in the pathogenesis of ANCA disease. However, no other laboratory has yet reported confirmation of either the frequency of anti-LAMP-2 antibodies in patients or the pathogenicity of these antibodies in animal models.
Origin of the antineutrophil cytoplasmic autoantibody autoimmune response
So far in this review, the focus had been on the pathogenesis of disease in patients who have circulating ANCA. Another important issue is the origin and persistence of the autoimmune response that leads to the pathogenic events. Two mechanisms that have been proposed for the origin of the ANCA autoimmune response are molecular mimicry of the autoantigen by a bacterial peptide [3] and induction of autoimmunity through an immune response to the complementary peptide of the autoantigen that secondarily results in antibodies against the autoantigen [45] .
Kain et al. [3] have proposed that molecular mimicry of LAMP-2 by a the bacterial adhesin FimH can induce circulating anti-FimH antibodies that crossreact with LAMP-2, which can cause pauci-immune glomerulonephritis and small vessel vasculitis. A LAMP-2 peptide has 100% homology to FimH. Rats immunized with FimH developed antibodies to rat and human LAMP-2 and developed pauci-immune necrotizing glomerulonephritis. The authors thus postulate that infection by fimbriated bacteria bearing FimH induces an immune response that crossreacts with LAMP-2 resulting in the mediation of pauci-immune necrotizing glomerulonephritis and vasculitis. This is a paradigm shifting concept that undoubtedly will result in follow-up studies from many laboratories. To date, no confirmatory reports have been published.
Another novel theory for induction of the ANCA autoimmune response postulates that the initial immune response is against an epitope that is on antisense peptide (complementary autoantigen peptide) or a mimic of an antisense peptide rather than against a sense autoantigen peptide (Fig. 1) [45, 46 ] . Patients with PR3-ANCA disease have not only circulating antibodies against sense PR3 peptides but also a separate set of antibodies against antisense complementary PR3 peptides (anticPR3). Theoretically, an immune response to a complementary PR3 peptide produces anticPR3 antibodies, which in turn cause the development of anti-idiotypic antibodies that recognize not only the idiotope on the anticPR3 antibodies but also the portion of the PR3 molecule to which the peptide is complementary. The cPR3 peptide could arise endogenously from transcription of PR3 antisense, or could be introduced exogenously, for example as a component of an infectious microorganism that has a peptide that mimics cPR3. Interestingly, several pathogens that are associated with the development of PR3-ANCA (including Ross river virus, Staphylococcus aureus and Entamoeba histolytica) have constituent mimics of cPR3 [45] .
An interesting outgrowth of the theory of autoantigen complementarity is the identification of autoantibodies with dual reactivity to plasminogen and complementary PR3 in patients with ANCA disease [47, 48 ] . Further, patients with antiplasminogen antibodies are at increased risk for thrombotic complications. Plasminogen has an epitope that also occurs in cPR3, thus suggesting that they arise secondary to molecular mimicry [47] . Berden et al. [48 ] noted that patients with antiplasminogen antibodies had greater percentages of glomeruli with fibrinoid necrosis and cellular crescents, and had more severe renal insufficiency, suggesting a possible role in the pathogenesis of glomerulonephritis.
The development of ANCAs can be associated with persistent bacterial or viral infections, especially bacterial endocarditis [49 ,50 ] . In this setting, ANCAs may not result in the induction of glomerulonephritis or vasculitis, and appropriate therapy should be directed at eliminating the infection. Clues that a patient may have infectionassociated ANCAs are dual PR3-ANCA and MPO-ANCA positivity and concurrence of other autoantibodies, such as anticardiolipin antibodies and cryoglobulins [50 ] . Patients with nonpathogenic infection-associated ANCAs may have glomerulonephritis caused by infectioninduced immune complex glomerulonephritis (e.g. cryoglobulinemic glomerulonephritis) even though they do not have ANCA disease.
Drugs and other environmental factors may induce an ANCA autoimmune response. Silica is a risk factor for ANCA disease [51, 52] . ANCA disease can be caused by drugs, including propylthiouracil, hydralazine, D-penicillamine, allopurinol, minocycline and anti-TNF agents [7, 8, 53 ]. Visavachaipan et al.
[53 ] recently reviewed their experience with seven patients with Graves' disease who received propylthiouracil and developed ANCA disease. Proteinuria ranged from 0.49 to 2.9 g/day. Mean serum creatinine was 2.05 mg/dl with creatinine clearance of 44 AE 35 ml/min. Renal remission occurred in all patients after propylthiouracil was withdrawn and steroids administered.
Regulation of the antineutrophil cytoplasmic autoantibody autoimmune response
Once an ANCA autoimmune response develops, regulation of the response probably is critical in whether or not it will be pathogenic. In fact, Cui et al. In addition, patients with active ANCA disease who had increased circulating CD4(þ) Foxp3(þ) cells had a more rapid disease remission. Chavele et al. [58 ] studied MPO-specific T cell reactivity and regulation during disease remission and concluded that MPO-specific T cell frequencies are regulated during disease remission. They also noted that FoxP3 levels were diminished in patients compared with controls. This same group also studied serum interleukin (IL)-17A and IL-23, and the frequency of IL-17-producing autoantigen-specific T cells in patients with ANCA disease [59 ] . Serum IL-17A levels were significantly elevated in acute disease compared to healthy controls. Patients with elevated levels of IL-23 compared to those with low IL-23 had more active disease and higher ANCA titers. The authors conclude that the Th17 axis is important in the modulation of ANCA disease. Further, Lamprecht et al. [60] have proposed that modulation of the T cell responses in tissue, including Th1 and Th17 responses and dysfunctional regulatory T cells, could be responsible for the distinctive aggressive granulomatous inflammation of Wegener's granulomatosis. In line with this study, Wilde et al. [61 ] have emphasized the importance of evaluating not only circulating T cells but also tissue T cells, especially at sites of injury.
To date, there has not been extensive study of the role of T cells in animal models of ANCA disease. One recent study uses a mouse model of autoimmune glomerulonephritis that results from apparent synergy between anti-GBM and anti-MPO antibodies [62, 63 ]. In this model, anti-MPO CD4þ T cells appear to act with macrophages to amplify glomerular injury [62] . Using this model, Gan et al. [63 ] also observed that mice deficient in the Th17 effector cytokine IL-17A were nearly completely protected from developing glomerulonephritis.
Thus, there is evidence that T cells are involved in both the genesis and regulation of the ANCA autoimmune response, as well as effector events in ANCA disease.
Conclusion
Clinical, in-vitro experimental and animal model data support a direct pathogenic role for ANCAs in the pathogenesis of ANCA disease (Fig. 1) . In-vitro evidence indicates that ANCA IgG can activate neutrophils and monocytes through Fc receptor and Fab 0 2 binding resulting in adhesion to endothelial cells and release of cytotoxic factors. In-vivo animal model evidence indicates that ANCAs can cause renal and systemic pauci-immune necrotizing vasculitis that closely resembles human ANCAassociated vasculitis. This evidence is better for anti-MPO than for anti-PR3 antibodies. T cells appear to play important roles in the genesis of the autoimmune response, as well as in the orchestration of tissue injury. The origin and pathogenesis of ANCA disease involves interplay between multiple environmental, genetic and biological processes that initiate the pathogenic autoimmune response, cause the acute lesions, and lead to chronic progression of lesions if therapy is not fully effective. 
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